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Rebound of plasma viremia
Reservoirs
Animal modelAttempts to ﬁnd a cure for HIV infection are hindered by the presence of viral reservoirs that resist highly ac-
tive antiretroviral therapy. To identify the properties of these reservoirs, four SIV239-infected Rhesus ma-
caques were treated with combined antiretroviral therapy (cART) for 1 year. While plasma viral RNA
(vRNA) was effectively suppressed, a systemic analysis revealed that vRNA was distributed in the following
order: lymphatic tissues>lungs and intestine>other tissues. Histochemistry yielded no cells with viral sig-
nals. To increase the chance of detection, two additional SIV-infected animals were treated and analyzed
on Day 10 after the cessation of cART. These animals exhibited similar vRNA distribution patterns to the for-
mer animals, and immunohistochemistry revealed Nef-positive T lymphocytes predominantly in the follicles
of mesenteric lymph nodes (MLNs). These data suggest that lymphatic tissues, including MLNs, contain major
cellular reservoirs that cause rebound of plasma viremia upon cessation of therapy.
© 2011 Elsevier Inc. All rights reserved.Introduction
Highly active antiretroviral therapy (HAART), which consists of
three or more anti-HIV-1 drugs, is currently the primary choice of
therapeutic intervention for HIV-1-infected individuals (Department
of Health and Human Services (DHHS), 2011). The circulating viral
loads in these patients are, in most cases, effectively suppressed
below the limit of detection (b50 copies/ml of plasma) by HAART
(Richman, 2001). However, the virus loads promptly rebound to pre-
treatment levels upon cessation of HAART (Chun et al., 1999), which
suggests the persistence of viral reservoirs during the combined anti-
viral therapy. Therefore, to achieve a complete cure of HIV-1 infec-
tion, it is essential to eradicate these viral reservoirs.
Resting CD4+ T lymphocytes have been identiﬁed as a viral reser-
voir (Chun et al., 1997; Finzi et al., 1997; Wong et al., 1997). These
cells harbor intact viral genomes integrated into their chromosomes
and produce infectious virus particles when they are reactivated in
response to stimulation. It is noteworthy that the estimated half-lifeology Research Bldg, Institute
, Shogoin, Sakyo ward, Kyoto,
ashi).
rights reserved.of a resting CD4+ T cell is more than 44 months (Siliciano et al.,
2003), which provides a theoretical basis for the source of the virus
that rebounds upon cessation of long-term, successful HAART. Resting
CD4+ T lymphocyte is probably not the only reservoir of HIV-1. In the
majority of patients on HAART, the rebounding viral genotypes
detected in the plasma upon cessation of therapy were dissimilar to
the genotypes extracted from resting CD4+ T cells or from virus par-
ticles recovered from cells that were collected before interruption of
the therapy (Chun et al., 2000).
Follicular dendritic cells (FDCs) have also been proposed as a viral
reservoir (Spiegel et al., 1992). These cells are present in the follicles
formed in all secondary lymphoid tissue. Rather than being infected
with virus, FDCs retain infectious HIV-1 particles on the cell surface
and transfer them to CD4+ T lymphocytes (Burton et al., 2002).
Since FDCs retain numerous virus particles, the genomes of which ex-
hibit greater diversity than those in other tissues or cells and which
reportedly hold infectious particles for months to years, it seems like-
ly that these cells serve as archives of infectious virions (Keele et al.,
2008).
The recently developed method for ultrasensitive detection of
plasma viral burdens has revealed that patients who have HAART-
controlled viremia (below the detection limit by clinical criteria; i.e.,
b50 copies/ml plasma) over several years still harbor minuscule
108 M. Horiike et al. / Virology 423 (2012) 107–118amounts of virion-associated RNA in the circulation (Palmer et al.,
2008), suggesting ongoing viral replication, i.e., “residual viremia”.
The potential for ongoing HIV-1 replication during HAART is sup-
ported by evidence of env gene evolution in patients receiving
HAART (Frost et al., 2001; Martinez et al., 1999), as well as the detec-
tion in patients on HAART of 1-LTR and 2-LTR circles, episomal HIV-1
cDNAs, the presence of which most likely reﬂects recent infection
(Sharkey et al., 2000, 2005). A transient increase in the number of
2-LTR circles, probably reﬂecting an increase in the number of failed
attempts to integrate into the host cell genome, was detected in ap-
proximately 30% of infected individuals who were receiving HAART,
when an integrase inhibitor was added as treatment intensiﬁcation
(Buzon et al., 2010). Based on these lines of evidence, it is conceivable
that certain cell types, as yet to be identiﬁed, allow productive repli-
cation of HIV-1 during HAART. Although HAART theoretically arrests
de novo virus replication, these unidentiﬁed reservoirs appear to be
refractory to the antiviral effects of the regimen through unknown
mechanisms.
It is postulated that viral reservoirs in the host retain HIV-1 during
HAART as follows: resting CD4+ T lymphocytes store inducible viral
genomes, FDCs archive infectious particles, and unidentiﬁed cells
support productive viral replication cycles. It remains to be revealed
whether other cell types serve as viral reservoirs using other mecha-
nisms, and which cell type is the most important for sequestering
HIV-1.
Peripheral blood samples from volunteer patients have been used
in studies to identity HIV-1 reservoirs (Brennan et al., 2009; Chun et
al., 2000; Sharkey et al., 2011). However, HIV-1 predominantly repli-
cates in CD4+ T lymphocytes in the lymphoid tissues (Embretson et
al., 1993; Pantaleo et al., 1993), particularly the intestine, which is
home to 70–90% of all lymphocytes in the body and which is severely
affected during the acute phase of infection (Brenchley et al., 2004;
Guadalupe et al., 2003), determining prognosis. Therefore a systemic
analysis, in addition to existing studies on peripheral blood, would
elucidate the mechanisms underlying rebound of plasma viremia
upon discontinuation of HAART. Since it is unethical to collect various
tissues from patients for analysis, an alternative model system is re-
quired. In this regard, the SIV/macaque model, which has been useful
in understanding HIV-1 infection, is suitable for investigations of viral
reservoirs using a systemic analysis (Dinoso et al., 2009; North et al.,
2009).
Using the SIV239/macaque system, we investigated HIV-1 reser-
voirs during combined antiviral therapy (cART). First, we conducted
a systemic analysis of SIV-infected Rhesus macaques that received
cART for an extended period. SIV239 has been extensively used as a
tractable animal model for HIV-1 in studies of replication, pathogen-
esis, and vaccine development. In addition, this virus causes almost
complete depletion of CD4+ T lymphocytes in the intestine (Veazey
et al., 1998), as HIV-1 does in patients who suffer from AIDS.Table 1
Efﬁcacies of commercially available anti-HIV-1 protease inhibitors against SIV239 and
HIV-1 IIIB.
Compounds EC50a (nM) EC50
ratiob
SIV239 HIV-1 IIIB
Saquinavir 18.5 22.7 0.8
Lopinavir/ritonavir 52.2 35.6 1.5
Atazanavir 80.0 16.9 4.7
a 50% effective concentration.
b EC50 value against SIV239 divided by the EC50 value against HIV-1 IIIB.Results
Establishment of anti-SIV239 cART regimen with oral administration
Before the experimental infection of macaques with SIV, we estab-
lished an antiretroviral regimen that is applicable to SIV239 infection
in the Rhesus macaque model. Given that NNRTIs do not suppress
replication of SIV (Balzarini et al., 1995), anti-HIV-1 drugs belonging
to this class were excluded from consideration. Regarding NRTIs, sev-
eral studies have conﬁrmed that Tenofovir (TDF) and its pro-drug
PMPA are effective against SIV. Some studies have used Zidovudine
(AZT) and Lamivudine (3TC) to suppress SIV replication in vitro and
in vivo (Balzarini et al., 1995; Benlhassan-Chahour et al., 2003).
Based on the results of these studies, we included TDF (Viread) and
AZT/3TC (Combivir) in our regimen. Regarding protease inhibitors(PIs), Saquinavir (SQV) has been shown to be effective against SIV
in vitro (Giuffre et al., 2003; Witvrouw et al., 2004). When we initiat-
ed this study, the anti-SIV efﬁcacies of other commercially available
PIs had not yet been reported. To determine which PI to include in
our cART, we examined three commercially available PIs – SQV, Lopi-
navir/Ritonavir (LPV/RTV; Kaletra), and Atazanavir (ATV; Reyataz) –
in the MT-4/MTT assay. This assay, which was originally developed
to measure cell proliferation, was used to evaluate inhibition of
virus-induced killing of human T-lymphoid MT-4 cells in the pres-
ence of increasing amounts of the drugs (Pauwels et al., 1988).
Along with SIV239, HIV-1 IIIB was employed in the assay as a control.
All of the compounds tested suppressed the activity of SIV239. The
EC50 values for SQV were 18.5 nM against SIV and 22.7 nM against
HIV-1 (Table 1 and Supplemental Fig. 1). The EC50 ratio, i.e., the
EC50 value against SIV divided by the EC50 value against HIV-1, was
0.8 (Table 1). The EC50s against SIV239 and the EC50 ratios of the
other two drugs were: 52.2 nM and 1.5, respectively, for LPV/RTV;
and 80.0 nM and 4.7, respectively, for ATV. Pharmacokinetic informa-
tion on these drugs is available, and the half-life in the circulation in
humans is: 1–2 h for SQV; 5–6 h for LPV/RTV; and 7 h for ATV
(Department of Health and Human Services (DHHS), 2011). Taking
into account the EC50, the half-life (which deﬁnes the required fre-
quency of administration to maintain the drug level), and cost-
effectiveness, we included LPV/RTV in our regimen.
Drug administrationwas instituted per os, to effectivelymodel theme-
tabolism and pharmacokinetics of the antiviral drugs in patients. The dos-
age and administration of these drugs are described in the Materials and
methods section. To assess whether a given dosage resulted in a measur-
able concentration of the drug in the circulation even after a long interval,
blood samples were collected from six monkeys at 14 h after intake and
the antiviral effect in plasma was determined by titration. The drug con-
centrations in the animals' blood ranged from 7.2 to 29.5 μM (LPV/RTV
equivalent); these levels are 5- to 20-fold higher than those recom-
mended for adult patients (1.5 μM for LPV/RTV equivalent)
(Department of Health and Human Services (DHHS), 2011). Plasma sam-
ples from two representative animals, which had already beenmeasured
in the biological assay, were also subjected to HPLC. The results of the
HPLC analysis revealed drug concentrations comparable to those deter-
mined by the biological assay: 16.1 μM for one animal (20.0 μM by the
MTT assay) and 25.7 μM for the other animal (24.8 μM by the MTT
assay), thus justifying our use of the biological assay to measure levels
of antiviral activity in the circulation of SIV-infected animals during ther-
apy. Based on these results, we ﬁnalized the regimen.Efﬁcacy of the cART regimen for macaques infected with SIV239
The establishment of the anti-SIV regimen enabled us to conduct ani-
mal experiments. Seven Rhesusmacaqueswere inoculated intravenously
with 2000 TCID50 of the SIV239 virus stock. All animals exhibited an initial
peak of viremia at 2 weeks post-inoculation (pi) (median, 2.2×107 cop-
ies/ml; range, 7.9–60.0×106 copies/ml, Fig. 1). At 8 weeks pi, when the
viral loads decreased from the initial peak and plateaued (median,
1.3×105 copies/ml; range, 1.1–4.9×105 copies/ml), the cART was
Fig. 1. Effects of cART on plasma viral loads. Seven Rhesus macaques were inoculated with SIV239. Four animals, MM491, MM499, MM528, and MM530 (solid lines), were treated
with cART (shaded areas). Animals MM510, MM496, and MM521 (dotted line) served as untreated controls. The detection limit of our RT-PCR assay is 200 RNA copies/ml, and
samples with levels below the level of detection are plotted as 200 RNA copies/ml. , time of euthanasia.
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MM530; designated as group A).
Upon drug administration, the plasma viral RNA (vRNA) levels in
these animals promptly started to decrease. There was an inverse in-
clination between set point plasma vRNA load and duration to sup-
press vRNA to the detection limit (200 copies/ml). The vRNA of
MM491, whose set point viral RNA level was the lowest in the
group 1.1×105 copies/ml, fell below the detection limit in 2 weeks.
MM499 and MM528, whose plasma vRNAs were 4.4×105 and
1.3×106 copies/ml at the initiation of cART, took 5 and 6 weeks, re-
spectively. After nine weeks of treatment, the viral burden of
MM530, which had the highest level in the group at 4.9×106 cop-
ies/ml, was undetectable. Plasma vRNA levels of all animals on cART
had fallen below the limit of detection by 17 weeks pi. When
HAART was applied to SIV/pigtailed macaque or RT-SHIV/rhesus ma-
caque models, it took 8 and 18 weeks, respectively, to suppress circu-
lating vRNA to below the detection limit (Dinoso et al., 2009; North et
al., 2009). When considering variables from previous studies, includ-
ing virus strain, drug combinations, detection limit of vRNA measure-
ment, and initiation of treatment of these studies, it is conceivable
that the cART approach devised in the current study is as potent in
terms of the progress to viral containment.
To relate our results to previous studies on vRNA declines for HIV-
1 and SIV following antiviral therapy, we examined the levels of vire-
mia in our infected monkeys during the ﬁrst few weeks after the ini-
tiation of therapy (Table 2 and Supplemental Fig. 2). Each individual
monkey followed a similar pattern of viral decay: an initial rapid
and exponential reduction by almost 2.5 orders of magnitudeFig. 2. Nef-expressing cells detected in the iMLNs of animal MM511. (a) The section was
expressing cells and CD35-positive FDCs in the follicle of an iMLN from MM511. The sam
anti-CD35 mouse monoclonal antibody (blue). Original magniﬁcation, ×40. The insets cont(comprising the ﬁrst phase, which is presumably associated with
short-lived infected cells), followed by a slower exponential decline
of 1.5 orders of magnitude (the second phase, which is presumably
associated with long-lived infected cells). The observed biphasic
decay of viral burdens was consistent with previous ﬁndings from
studies on SIV models and patients with HIV-1 (Dinoso et al., 2009;
Murray et al., 2007; Perelson et al., 1997; Perelson and Nelson,
1999). Decay rates for the ﬁrst and second phases were deduced by
employing mathematical modeling (Table 2). The decay rates of the
ﬁrst phase ranged from 0.495 (for MM491) to 0.853 (for MM499),
and those of the second phase ranged from 0.028 (for MM491) to
0.089 (for MM499). The decay rates of plasma vRNA loads during
the ﬁrst phase in patients with HIV-1 on HAART, consisting of LPV/
RTV, Efavirenz, 3TC, and TDF, exhibited comparable numbers to
those in the current study, ranging from 0.6 to 1.4 (Markowitz et al.,
2003). Mean half-lives of (log 2/a=) 1.13 for the ﬁrst phase and
(log 2/μM) 14.24 days for the second phase were comparable to
those observed in patients with HIV-1 on HAART. Half-lives of HIV-1
RNA in the circulation of HIV-1-infected patients on suppressive
ART, consisting of Indinavir and Efavirenz, ranged from 0.6 to
2.0 days for the ﬁrst phase and 5.2 to 35.6 days for the second phase
(Havlir et al., 2003). Comparison of the viral decay rates derived in
the current study with those derived in previous reports (Perelson
et al., 1997) gave statistically insigniﬁcant results (P=0.667 for the
ﬁrst phase, and P=0.662 for the second phase). These results suggest
that the virologic response of SIV infected Rhesus macaques to cART,
as reported in a recent study (Dinoso et al., 2009), is comparable to
the response of HIV-1-infected patients to HAART.stained with the anti-SIV Nef mouse monoclonal antibody. (b) Juxtaposition of Nef-
ple was stained using the anti-SIV Nef mouse monoclonal antibody (brown) and the
ain a higher-magniﬁcation, ×126 equivalent (original magniﬁcation, ×63).
Table 2
Decay rate and half-life derived by mathematical modeling of short- or long-lived infected cells in group A monkeys.
Animal
ID
Short-lived infected cells Long-lived infected cells
Decay rate : a (day−1) Half-life : log2/a (days) Decay rate : μM (day−1) Half-life : log2/μM (days)
MM491 0.495 [0.405–0.605]a 1.400 [1.146–1.711] 0.028 [0.000–0.141] 24.76 [4.916–∞]
MM499 0.853 [0.807–1.287] 0.813 [0.539–0.859] 0.089 [0.083–0.100] 7.753 [6.931–8.402]
MM528 0.707 [0.661–0.746] 0.980 [0.929–1.049] 0.061 [0.045–0.070] 11.44 [9.846–15.44]
MM530 0.523 [0.372–0.575] 1.325 [1.205–1.863] 0.053 [0.035–0.064] 13.00 [10.85–19.86]
Mean 0.645 1.130 0.058 14.24
S.D. 0.168 0.279 0.025 7.351
a Values in parentheses represent the lower and upper 68% conﬁdence intervals, calculated by a bootstrap method in which each experiment was simulated 1000 times.
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ma vRNA (typically less than 50 copies/ml) when the therapy works
as expected. To estimate suppression levels achieved by the regimen
used in the current study, selected plasma samples with adequate vol-
ume from animals in group A were subjected to another quantitative
real-time PCR assay with a lower detection limit. Using 1.5-ml plasma
samples, which were collected at 29, 42, and 52 weeks pi, and at eu-
thanasia, particle-associated vRNA was extracted and ampliﬁed. All
of these samples yielded less than 20 copies/ml of vRNA loads
(Table 3), except for those collected at 42 and 52 weeks pi (44 and
47 copies/ml, respectively) fromMM530, which exhibited the highest
plasma vRNA at the start of cART (4.9×106 copies/ml) and required
the longest duration to suppress vRNA to 200 copies/ml (9 weeks).
These results conﬁrm that the regimen established in the current
study is as suppressive as those applied to patients. Based on the pro-
gression to viral containment, decay rates, and suppression levels, we
concluded that the cART established in the current study is compara-
ble to therapies used to treat patients with HIV-1 and suitable to pur-
sue viral reservoirs during therapy. The suppressed viral burdens of
the treated animals were maintained below the limit of detection
throughout the course of treatment (up to 52 weeks). In contrast,
the viral burdens of the untreated animals (MM496, MM510, and
MM521) remained at >1.0×105 copies/ml until the day of necropsy
(Fig. 1). Assuming a limit of viral detection of 200 copies/ml, there
was a statistically signiﬁcant difference in the plasma vRNA levels be-
tween the two groups of animals at week 42 (Pb0.05).
During the entire course of cART, the levels of antiviral activity in
the plasma samples of animals MM491, MM528, and MM530
assessed by MT-4/MTT assay were above the recommended trough
level for adult patients (for MM491: range, 3.5–17.8 μM LPV/RTV
equivalent; for MM528: range, 6.0–24.9 μM LPV/RTV equivalent; for
MM530: range, 8.2–14.2 μM LPV/RTV equivalent) (Table 4). Even in
the remaining animal, MM499, in which the circulating concentration
of the activity was below the recommended trough level at the two
time-points tested, at 10 weeks pi and at autopsy, during the course
of antiviral therapy, the plasma vRNA levels were below the limit of
detection. None of the treated animals exhibited a transient surge in
vRNA level during the entire course of the therapy. Certain clinical
conditions are known to be side-effects of antiviral drug treatment
(Department of Health and Human Services (DHHS), 2011). Among
the drugs employed in the present study, TDF potentially causes
renal complications (Van Rompay et al., 2004) and LPV/RTV canTable 3
Plasma viral loads of selected samples measured by RT-PCR with a lower detection
limit (20 copies/ml) in group A animals during cART.
Animals
ID
Plasma viral loads (copies/ml)
29 wpi 42 wpi 52 wpi At autopsya
MM491 b20 b20 b20 b20
MM499 b20 b20 b20 b20
MM528 b20 b20 b20 b20
MM530 b20 44 47 b20
a MM491, 63 wpi; MM499, 64 wpi; MM528, 61 wpi; MM530, 65 wpi.induce abnormal lipid metabolism. In general, no signiﬁcant adverse
effects were noted for the drugs employed in the present study. We
conclude that the antiretroviral therapy regimen established in the
current study is as effective as the combined antiretroviral therapy
applied to patients with HIV.
Higher titers of vRNA were detected in the lymphoid tissues of
virus-infected animals undergoing antiretroviral therapy
The establishment of an effective antiretroviral therapy regimen
for SIV-infected monkeys was a prerequisite for the identiﬁcation of
virus reservoirs during combined antiviral therapy. To this end, we
considered two important questions: ‘Is virus replication maintained
during the therapy?’, and ‘If active virus replication persists, are there
particular anatomic compartments that allow preferential virus
replication?’
To answer these questions, we looked for the presence of vRNA in
a variety of tissues collected from animals receiving cART over a peri-
od of 1 year. Total RNA was extracted from each tissue and subjected
to real-time reverse transcription (RT)-PCR. Table 5 summarizes the
results of RT-PCR for four animals in group A that were subjected to
analysis at the end of the 1-year cART regimen, along with a represen-
tative animal that was not given treatment (MM521); all the animals
were euthanized at between 61 and 68 weeks pi. In the untreated
monkey (MM521), vRNA was detected in all the tissues examined,
with the exception of the brainstem. In the lymphoid tissues, higher
titers of vRNA (approximately 1.0×108 copies/μg total RNA) were
detected. In the gastrointestinal tract, lungs, and vagina, in which
the resident CD4+ T-lymphocyte population consists mainly of
CCR5+ memory cells (the preferred target of HIV-1 and SIV) (Douek
et al., 2003; Meng et al., 2000; Veazey et al., 2000), the vRNA titers
were approximately 1.0×106 copies/μg of total RNA. Lower levels of
vRNA were detected in the non-lymphoid tissues (heart, liver, and
kidneys) and the central nervous system (cerebrum and cerebellum).
In the group A macaques, the vRNA titers in several tissues were
much lower than those found in the untreated animals. The non-
lymphoid tissues and central nervous system did not contain measur-
able amounts of vRNA. Low levels of vRNA were detected in the effec-
tor sites, such as the intestine (up to 6.5×104 copies/μg total RNA),
lungs, and vagina (up to 6.5×103 copies/μg total RNA). Statistical
analysis of vRNA burdens revealed signiﬁcant reductions in the jeju-
num and rectum of animals in group A as compared to those ofTable 4




10 wpi 20 wpi 32 wpi 42 wpi 56 wpi At autopsyb
MM491 3.5 15.9 12.1 17.8 7.9 5.2
MM499 0.6 2.3 4.4 11.4 1.7 0.9
MM528 16.0 24.9 6.6 7.7 6.0 9.3
MM530 9.4 12.4 8.2 14.2 11.3 11.3
a LPV/RTV equivalent concentration.
b MM491, 63 wpi; MM499, 64 wpi; MM528, 61 wpi; MM530, 65 wpi.
Table 5
Viral RNA burdens in various tissues collected from SIV-infected macaques.
N.D., no data; CNS, central nervous system; LNs, lymph nodes; iMLNs, inferior mesenteric lymph nodes; sMLNs, superior mesenteric lymph nodes.
Viral RNA (vRNA) levels greater than detection limit (2900 copies/µg total RNA) are represented in bold. vRNA levels are coded in grayscale as follows: white boxes, b2900;
light-gray boxes, b1.0×105; dark-gray boxes, b1.0×107; black boxes, >1.0×107.
aViral loads in plasma.
Table 6
Viral loads in plasma samples of animals in group B.
Animal
ID
Plasma viral loads (copies/ml)
0 wpi 2 wpi 8 wpi 38 wpi 46 wpi At autopsya
MM508 b200 8.4×106 2.6×105 3.8×104 b200 b200
MM511 b200 7.7×106 3.1×105 1.1×105 b200 1.4×103
The animals were treated with cART from 38 wpi to 46 wpi.
a 47.5 wpi.
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expression in those tissues, although incompletely. Compared to the
above-mentioned tissues, higher levels of vRNA (approximately
1.0×105 copies/μg of total RNA) were detected in the lymphoid tis-
sues. Of note, both the superior and inferior mesenteric lymph
nodes (sMLNs and iMLNs, respectively) were among the tissues that
contained the highest titers of vRNA in animals on cART. Statistical
analysis of vRNA in the lymphatic tissues also revealed signiﬁcant
suppression in group A as compared to controls (iliac and subman-
dibular lymph nodes and iMLNs, P=0.03).
To identify the cell type(s) that support vRNA synthesis and, po-
tentially, allow viral proteins to be produced during ART, we prepared
tissue sections from the animals in group A and subjected them to in
situ hybridization (ISH) and immunohistochemistry (IHC). While
these tissues yielded no positive signals, the same staining techniques
detected vRNA-positive cells and viral-protein-positive cells in tissue
sections prepared from untreated animals (data not shown).
In summary, our initial questions were resolved as follows: the
presence of vRNA in the gut, lungs, vagina, and lymphoid tissues indi-
cated active viral replication in animals that were treated with cART
for 1 year, and the lymphatic tissues allowed preferential viral repli-
cation in these animals.
SIV Nef-producing T lymphocytes predominated in the follicles of the
MLNs from an animal that exhibited rebound of plasma viremia upon
cessation of cART
Quantitative PCR analysis of vRNA in a variety of tissues collected
from SIV-infected animals that were on prolonged chemotherapy
(i.e., the animals in group A) indicated that the lymphatic tissues
acted as the anatomic compartment for active virus replication during
antiretroviral therapy. However, we were unable to identify histo-
chemically any vRNA-positive or viral-protein-positive cells in thetissue sections prepared from these animals. This discrepancy was
likely due to the lower sensitivity of these staining techniques as
compared to PCR. We assumed that cessation of ART would result in
rebound of plasma viremia, thereby promoting the transcription
and translation of viral genes to levels detectable by the histochemi-
cal staining techniques employed in the present study. Based on this
assumption, we took advantage of the rebound of plasma viremia as
a surrogate approach to identify the viral reservoir(s) during cART.
Thus, two Rhesus macaques (MM508 and MM511, designated as
group B animals) were inoculated with the same SIV239 virus stock
as was used to inoculate the group A animals. The group B animals
exhibited an initial peak of viremia at 2 weeks pi (range, 7.7–
8.4×107 copies/ml; Table 6), and the viral loads decreased and stabi-
lized from 8 wpi onwards. Upon initiation of cART at 38 wpi, the
levels of virus decreased rapidly and eventually fell below the limit
of detection. The suppressed viral burdens were maintained until ces-
sation of the treatment at 46 weeks pi. We attempted to determine
the time-point at which the levels of viral gene transcription and
translation were just above the detection limit of our staining. Since
we envisioned that rebound of plasma viremia would take place
within 2 weeks of interruption of therapy, animals were euthanized
for necropsy on Day 10 after cessation of cART. The viral load in the
plasma of animal MM511 was 1400 copies/ml, while that of animal
Table 7
Viral RNA burdens in various tissues collected from animals in group B.
PVL, plasma virus load; N.D., no data; CNS, central nervous system; LNs, lymph nodes;
iMLNs, inferior mesenteric lymph nodes; sMLNs, superior mesenteric lymph nodes.
Viral RNA (vRNA) levels greater than detection limit (2900 copies/µg total RNA) are
represented in bold. vRNA levels are colored in grayscale as follows: white boxes,
b2900; light-gray boxes, b1.0×105; dark-gray boxes, b1.0×107.
112 M. Horiike et al. / Virology 423 (2012) 107–118MM508 was below the limit of detection (Table 6). Thus, one animal
was exhibiting rebound of plasma viremia while the other animal had
not yet reached that stage when they were killed for analysis.
The overall tendency of the vRNA distribution in the group B ani-
mals was similar to that observed in the group A animals, with theFig. 3. Nef-positive T lymphocytes in the MLN of animal MM511. Tissue sections were staine
rabbit polyclonal antibody (red, b and e). (c) Superimposed image of a and b. Nef-positive T
cell is detected in the paracortical area of the sMLN. Original magniﬁcation, ×40.titers being somewhat higher in group B. Higher levels of vRNA
(>1.0×104 copies/μg total RNA) were detected exclusively in the
lymphoid tissues (Table 7). In MM511, the highest level of vRNA
was detected in the MLNs (>1.0×106 copies/μg total RNA). MM508,
in which the plasma viral load was below the limit of detection at eu-
thanasia, contained high levels of vRNA (>1.0×105 copies/μg of total
RNA), but only in the spleen and iMLN.
Based on the increased levels of vRNA transcription, we hypothe-
sized that higher levels of viral proteins were synthesized in these
two animals (MM508 and MM511) than in the group A animals. We
subjected all the lymphoid tissues collected from these two animals
to IHC, to identify viral-protein-producing cells. First, we focused on
MM511, which exhibited higher viral titers in the plasma and lym-
phoid tissues than MM508, and stained tissue sections from this ani-
mal with anti-Nef antibodies. IHC yielded Nef-positive cells (Fig. 2).
The viral-protein-positive cells were mainly localized to the globular
architecture in the lymph node cortex, most likely the lymphoid folli-
cles, and the Nef-positive cells bore morphologic characteristics sim-
ilar to those of T lymphocytes (Fig. 2a). To clarify the architecture
within which the Nef-producing cells were detected, we conducted
combined IHC with an anti-Nef antibody (visualized with DAB) and
an antibody directed against CD35 (visualized with VECTOR Blue).
CD35 is a cell surface marker for FDCs, which are found exclusively
in the follicles of the secondary lymphoid tissues. The combined
staining showed that Nef-positive cells and FDCs were present in
the same globular architecture, suggesting that the viral-protein-
producing cells were predominantly located in the follicles of the
lymph nodes of this animal. Moreover, staining revealed that the
Nef-producing cells were juxtaposed on the FDCs (Fig. 2b).
To conﬁrm the identity of the viral-protein-expressing cells, we
conducted combined immunoﬂuorescence staining with an anti-Nef
antibody (visualized with Alexa Fluor 488) and an anti-CD3 antibody
(visualized with Alexa Fluor 594). After extensive observations of the
stained sections under the microscope, we detected Nef-positive cells
in 16/305 sections prepared from a variety of lymphatic tissues col-
lected from animal MM511, and these viral-protein-expressing cells
were all positive for CD3 (Fig. 3 and Table 8). Of these 16 sections,
12 were prepared from MLNs and 4 from other anatomicald using the anti-SIV Nef mouse monoclonal antibody (green, a and d) and the anti-CD3
cells are clustered in the follicles of the iMLN. (f) Superimposed image of d and e. The T
Table 8
Numbers of immunohistochemistry sections examined from macaques in group B.
Nef expressing T cells Number of sections subjected
MM508 MM511
MLN Non-MLN MLN Non-MLN Total
Present in the follicles 0 0 9 3 12
Present in the paracortical area 1 0 3 1 5
Absent 50 85 34 255 424
MLNs; mesenteric lymph nodes.
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stituted around 75% of all the positive cells detected. In some sections,
Nef-positive cells were clustered in the follicles (Fig. 3c).
In animal MM508, which was subjected to analysis before re-
bound of plasma viremia had taken place, the staining revealed a sin-
gle Nef-positive cell that was also positive for CD3 (data not shown).
The frequency of positive cells in this animal was substantially lower
(one positive cell in 136 sections) than that in MM511.
In summary, in the animal that exhibited rebound of plasma vire-
mia after cessation of cART, almost all the viral-protein-synthesizing
cells, presumably productively infected cells, that were detected in
the MLNs were identiﬁed as T lymphocytes, most likely CD4+ T
cells. The vast majority of the virus-infected T cells were observed
in the lymphoid follicles during rebound of plasma viremia (Table 8).
Discussion
The presence in infected individuals of HIV-1 viral reservoirs that
persist during HAART impedes curing and complete eradication of
the virus. While studies have been conducted into the identity and
properties of the HIV-1 reservoirs (Brennan et al., 2009; Chun et al.,
2000; Sharkey et al., 2011), much remains to be learnt. We reasoned
that systemic analyses of infected individuals who were undergoing
intensive ART would advance the characterization of the viral reser-
voirs (Dinoso et al., 2009; North et al., 2009). Therefore, we analyzed
SIV-infected Rhesus macaques that underwent cART for 1 year. The
major ﬁnding of the current study is that lymphatic tissues, including
MLNs, contained higher numbers of cellular virus reservoirs that po-
tentially cause rebound of plasma viremia upon cessation of cART.
This assertion is based on the following observations: the lymphatic
tissues contained the highest levels of vRNA in all the animals, regard-
less of cART, and the viral-protein-expressing T cells were localized
predominantly to the MLNs of the animal that exhibited rebound of
plasma viremia after cessation of cART.
We ﬁnalized the drug dosages to be administered by monitoring
plasma trough levels of antiviral activity at 14 h post-consumption.
During this process we discovered that the drug metabolism of mon-
keys is somewhat higher than that of humans. To ﬁne-tune the drug
concentrations in the circulation, 50% of the dosage established in
the present study, corresponding to 150% of the dosage for a 60-kg
adult patient, was given to the same animals. The circulating drug
concentration at 14 h post-consumption yielded no measurable net
antiviral activity (data not shown). Therefore, it is necessary to deter-
mine an appropriate dosage for each drug prior to administration to
animals. In this regard, one of the monkeys in group A, MM499,
exhibited ﬂuctuating antiviral activity during the therapy. At 10 and
64 weeks pi, the antiviral activity in the blood was below the recom-
mended trough level for patients (1.5 μM) (Table 4). Despite the ﬂuc-
tuation of antiviral activity, the viral burden of this animal was
maintained below the limit of detection during the therapy, and sys-
temic analysis revealed levels of vRNA that were comparable to those
detected in the other three animals in group A (Table 5). That the
other three animals also exhibited ﬂuctuating concentrations of the
drug in the circulation underlines the importance of monitoring anti-
viral activity in circulation during therapy, to ensure that the admin-
istration schedule produces the expected antiviral activity.
RT-PCR analyses revealed that lymphatic tissues contained higher ti-
ters of vRNA than the other tissues in 4/4 SIV-infected macaques in
group A, and 2/2 animals in group B followed the same distribution of
vRNA (Tables 5 and 7). In SIV-infected monkeys treated with cART,
the Lamivudine concentration was more than 300-fold higher in the
gastrointestinal tract than in the peripheral lymph nodes (Bourry et
al., 2010). The ﬁnding of Bourry et al. explains our observation that che-
motherapywasmore effective at suppressing virus replication in the in-
testine than in the lymph nodes. It is possible that lymphatic tissues
serve as viral sanctuaries, especially when the amount of drugaccumulated in the tissues is insufﬁcient to suppress virus replication.
It should be noted that while viral load and drug concentration in the
plasma are easily monitored, they do not reﬂect precisely the virus rep-
lication/drug distribution in speciﬁc important anatomic
compartments.
Our results are also in good agreement with the results reported
by North et al., who performed a thorough analysis of a variety of tis-
sues collected from RT-SHIV-infected animals that were receiving
combined anti-viral therapy (North et al., 2009). The authors
employed RT-SHIV, which is a chimeric virus that carries the HIV-1-
derived RT gene on the backbone of SIV239, to model HAART to pa-
tients, in the context of SIV, since non-nucleotide reverse-
transcriptase inhibitors (NNRTIs), one of the core components of
HAART, do not suppress reverse transcription mediated by SIV RT
(Balzarini et al., 1995). Although the cART regimen devised in the cur-
rent study is unlike the HAART administered to patients, especially
with respect to the employment of certain drugs, the viral decay
rate in the circulation (calculated based on a two-compartment
model) is comparable to that observed in patients treated with the
multi-drug regimen (Murray et al., 2007; Palmer et al., 2008;
Perelson et al., 1997) (Table 2 and Supplemental Fig. 2). Therefore,
it is implied that the lymphatic tissues may harbor higher titers of
vRNA in HIV-1-infected patients on HAART, despite the viral burdens
in the circulation are clinically non-detectable. The caveat is that the
animals in the current study were on treatment for up to 1 year
only, which is a considerably shorter treatment period than that of
patients who have achieved successful virus containment since the
beginning of the HAART era. Given that the desired concentration of
the drug may not be reached in the lymphatic tissues, it is necessary
to devise a way to deliver in a preferential manner either antiviral
drugs or a speciﬁc injury to these compartments, in combination of
HAART, to achieve eradication of the virus, which is a crucial step to-
ward a complete cure for HIV-1 infection.
Histochemical analyses revealed that the SIV Nef protein was
expressed in T lymphocytes predominantly resident in the follicles
formed in the MLNs of animal MM511, which exhibited viral rebound
after cessation of cART (Fig. 3 and Table 8). Active virus replication in
the follicles of lymph nodes has been described (Folkvord et al.,
2005). Previous studies have suggested that lymphatic follicles serve
as preferred sites of virus replication, probably via FDCs and seques-
tration of virus-infected cells from cytotoxic T lymphocytes (CTLs).
FDCs, which may interact with CD4+ cells within the “enclave”, retain
infectious virus particles and produce TNF-α, which promotes HIV
replication (Thacker et al., 2009). HIV-1-speciﬁc CTLs fail to accumu-
late within lymphoid follicles, allowing unchecked virus replication in
this architecture (Connick et al., 2007). Taken together, these ﬁndings
support our observations of active viral protein synthesis in the lym-
phoid follicles.
The present study does not identify deﬁnitively the viral reser-
voirs. However, it does not rule out any of the proposed candidate
reservoirs: resting CD4+ T lymphocytes, FDCs, and unidentiﬁed cells
involved in ongoing virus replication during therapy. To place our re-
sults in the context of current thinking regarding putative viral reser-
voirs, we make the following important points:
114 M. Horiike et al. / Virology 423 (2012) 107–118North et al.(2009) detected proviral DNA in the resting CD4+ T-
lymphocyte fraction prepared from MLNs. Dinoso et al.(2009) recov-
ered replication-competent viruses in the cell fraction. It is possible
that the Nef-positive cells detected in the current study were reacti-
vated upon stimulation, thereby prompting resumption of the virus
replication cycle; the progeny viral particles from these cells would
initiate multiple rounds of replication in the T cells of the paracortical
area and the follicles of the lymph nodes.
We detected FDCs juxtaposed on the Nef protein-positive T lym-
phocytes. This observation is not deﬁnitive evidence that FDCs trans-
mit infectious viral particles to CD4+ T cells. Based on our
observations, we hypothesize that FDCs transmit virus to CD4+ T
cells or stimulate infected cells, so as to initiate viral rebound. An im-
portant caveat is that the animal in question was treated for only
8 weeks. Since FDCs are known to retain virus particles with their in-
fectivity intact for a certain period of time (Keele et al., 2008), it
would be informative to determine whether the interaction between
these two cell types occurs in animals that exhibit rebound after a
prolonged period of therapy, followed by cessation.
Although we have no direct evidence that unknown cells are in-
volved in ongoing viral replication during therapy, higher titers of
vRNA were detected in the lymphatic tissues, primarily the MLNs,
which suggests that certain cell types in this compartment allow
viral replication during chemotherapy. It is likely that the levels of
transcription of viral genes and of subsequent translation are too
low to be detected by the staining techniques employed in the cur-
rent study.
Based on our results, we postulate the following sequence of
events after the cessation of HAART in individuals infected with
HIV-1: in the follicles of the lymph nodes, such as MLNs, viruses
that are preserved in certain forms, such as intact genomes and infec-
tious particles, and with low-level ongoing replication, resume a pro-
ductive replication cycle, preceding other anatomical compartments,
when the concentration of the antiviral drug declines due to discon-
tinuation of therapy; thereafter, other anatomic compartments re-
sume productive viral replication owing to weakened containment
of the virus and higher accumulations of the drugs. The progeny
viral particles produced from the tissues subsequently enter the cir-
culation and cause rebound of plasma viremia, i.e., systemic viral
replication.
Considering that the state-of-the-art histochemical staining still
has lower sensitivity than PCR and that the vRNA distributions for an-
imals on ART and those with rebound of plasma viremia are similar,
analyses of animals undergoing rebound of plasma viremia after dis-
continuation of therapy could serve as a surrogate approach to study
virus reservoirs during HAART.
Fortunately, we captured ongoing rebound of plasma viremia in
animal MM511, whose viral burden was above the detection limit de-
ﬁned by the current staining technique. Further ﬁne-tuning in the du-
ration of therapy and timing of analysis after cessation would provide
better clues to the identity of virus reservoirs.
Materials and methods
Cells
Human embryonic kidney-derived 293T cells were cultured in
Dulbecco's modiﬁed Eagle's medium (D-MEM; Invitrogen, Carlsbad,
CA) that was supplemented with 10% fetal bovine serum (FBS;
HyClone Laboratories, Logan, UT) and 2 mM L-glutamine. Human T-
lymphoid MT-4 (Harada et al., 1985), Molt-4 (Koyanagi et al., 1986),
and M8166 (Shibata et al., 1991) cells were cultured in RPMI 1640
medium (Invitrogen) that was supplemented with 10% FBS, 2 mM so-
dium pyruvate, and 4 mM L-glutamine (R-10). Rhesus macaque
PBMCs were prepared from whole blood that was anticoagulated
with EDTA in lymphocyte separation medium (Nakalai Tesque,Kyoto, Japan). PBMCs were resuspended in R-10 medium that was
supplemented with 40 μg/ml gentamicin, 50 μM 2-mercaptoethanol,
and 25 μg/ml concanavalin A (Sigma-Aldrich, St. Louis, MO), and cul-
tured for 16–20 h at 37 °C. Before virus infection, the cells were cul-
tured for an additional 2 days in R-10 medium that was
supplemented with 40 μg/ml gentamicin, 50 μM 2-mercaptoethanol,
and 100 IU/ml recombinant human IL-2 (Imunace; Shionogi, Osaka,
Japan).
Viruses
The stock of SIV239 used in the tissue culture and animal experi-
ments was prepared in Rhesus macaque PBMCs inoculated with the
supernatant of a 293T-cell culture that was transiently transfected
with full-length infectious molecular clones of the virus (Kestler et
al., 1990). A stock of HIV-1 IIIB (Popovic et al., 1984) was prepared
from the supernatant of a Molt-4 cell culture that was chronically
infected with the virus. The SIV239 stock was titrated by infection
of M8166 cells, and the number of infectious units was calculated
by a method described previously (Reed and Muench, 1938).
Animal experiments
Female Rhesus macaques of Chinese or Indian origin, 4 kg in body
weight, were used for experimental infection with SIV239. Phleboto-
my and virus inoculation were carried out under anesthesia by intra-
muscular injection of a mixture of ketamine chloride (Ketalar; Daiichi
Sankyo, Tokyo, Japan) at 5–10 mg/kg and xylazine chloride (Celactal;
Bayer Healthcare, Leverkusen, Germany) at 1.5–2.0 mg/kg. For virus
infection, animals were inoculated intravenously with 2000-times
the 50% tissue culture infectious doses (TCID50) of SIV239. Animal ex-
periments were conducted in a biosafety level 3 animal facility, in
compliance with institutional regulations approved by the Committee
for Experimental Use of Nonhuman Primates of the Institute for Virus
Research, Kyoto University, Kyoto, Japan.
Extraction of active components from drug tablets or plasma
Saquinavir (Invirase; Chugai Pharmaceutical, Tokyo, Japan), Lopi-
navir/Ritonavir (Kaletra; Abbott Laboratories, Abbott Park, IL), and
Atazanavir (Reyataz; Bristol-Myers Squibb, New York, NY) were pur-
chased from their respective sources. Drug tablets were pulverized
with a pestle and mortar and dissolved in dimethyl sulfoxide
(DMSO; Wako Pure Chemical Industries, Osaka, Japan). The concen-
tration of each drug in DMSO was adjusted to 100 μg/ml with RPMI
1640 medium. To simulate the conditions of the drugs in the blood,
the drug solutions were diluted 10-fold with normal plasma from
Rhesus macaque. The drug extract was subsequently deproteinized
by mixing with methanol/acetonitrile (1:1). The soluble fraction
was evaporated, subsequently reconstituted in RPMI 1640 medium,
and adjusted to a concentration of 20 μg/ml. Plasma samples collected
from the animals were deproteinized, evaporated, and reconstituted
as described above. The efﬁcacy of the extraction employed in the
current study ranged from 30 to 50% when assessed using the anti-
HIV-1 drugs AZT, SQV, and RTV (data not shown).
Virus inhibition assay (MT-4/MTT assay)
The efﬁcacies of the PIs against SIV were assessed as described
previously (Sato et al., 1995), with minor modiﬁcations. Brieﬂy, ali-
quots of 5×103 MT-4 cells were dispensed into 96-well round-
bottomed tissue culture plates. Serially diluted extracts of the HIV-1
PIs or extracts of animal plasma samples were incubated with the
cells in quadruplicate at 37 °C for 1 h. The cells were then inoculated
with 1.8×103 TCID50 of SIV239 or 0.9×102 TCID50 of HIV-1 IIIB (mul-
tiplicity of infection [MOI] = 0.37 or 0.018, respectively). On Day 5
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(Nakalai Tesque).
Formulation and feeding of drugs and diet
The daily dosages of the drugs were half of those recommended
for an adult human, i.e., 300 mg of AZT and 150 mg of 3TC (as Combi-
vir; GlaxoSmithKline, London, UK), 150 mg of Tenofovir disproxil fu-
marate (TDF, as Viread; Japan Tobacco, Tokyo, Japan), and 400 mg
of Lopinavir and 100 mg of Ritonavir (as Kaletra; Abbott). To correlate
these dosages for a 4-kg Rhesus macaque with the recommended
dosage for an adult human, the body surface area (BSA) of the mon-
keys was computed as described previously (Du Bois and Du Bois,
1915, 1916). Using BSA and body weight, the Km factor for each ani-
mal was derived as described (Reagan-Shaw et al., 2008). The dosage
for the monkeys corresponded to 3-fold that for an adult human
weighing 60 kg. Among the drugs selected, Combivir (AZT/3TC) and
Kaletra (LPV/RTV) should be taken twice a day to maintain effective
drug concentrations. Therefore, two sets of drug/diet were prepared.
Formulation #1 contained AZT, 3TC, LPV, and RTV (150 mg, 75 mg,
200 mg, and 50 mg, respectively), while formulation #2 contained
all the drugs in formulation #1 plus TDF (150 mg). Thirty-ﬁve
grams of primate diet for Old World monkeys (Lab Diet 5048; PMI
Nutrition International, Henderson, CO), granulated with a bar blend-
er, was combined with the pulverized drugs. The drug/diet mixture
was further mixed with 75 g of squashed banana and formed into a
rectangular plate. The formulated drug/diet described above was
given to animals in place of their normal diet. Drug/diet formulation
#1 was given in the morning and formulation #2 was given 10 h
later, at intervals of 10 h and 14 h per day. Seven of the nine Rhesus
macaques that were fed the formulated drug/diet ingested 80–90%
of total mass within 2 h.
To assess the potential adverse effects of the high-dosage drug ad-
ministration employed in the current study, serum samples collected
from these animals before and during cART were submitted to ana-
lyses for the following clinical markers: blood urea nitrogen (BUN),
creatinine, total cholesterol, and triglycerides. No substantial ﬂuctua-
tionswere observed before and during cART in the values for BUN (av-
erage values: for MM491, 16.8 mg/dl; for MM499, 16.0 mg/dl; for
MM528, 16.7 mg/dl; and for MM530, 20.9 mg/dl), creatinine (average
values: for MM491, 0.5 mg/dl; for MM499, 0.6 mg/dl; for MM528,
0.5 mg/dl; and for MM530, 0.5 mg/dl), and total cholesterol (average
values: for MM491, 153 mg/dl; for MM499, 106 mg/dl; for MM528,
109 mg/dl; and for MM530, 132 mg/dl). Nearly all the samples ana-
lyzed fell within the normal value ranges for the above-mentioned
markers (data not shown). The triglyceride values from all the treated
animals, with the exception of MM499, increased upon onset of ART:
for MM491, the values ranged from 28 mg/dl at pretreatment to
99 mg/dl at maximum during cART; for MM528, from 21 mg/dl to
58 mg/dl; and for MM530, from 48 mg/dl to 129 mg/dl. The published
normal value range for triglycerides in Rhesus macaques is 24–42 mg/
dl (Fortman et al., 2001). At autopsy, lipid deposition in the liver was
noted in MM530, which exhibited the highest mean level of triglycer-
ides among the three animals, indicative of a certain degree of dysre-
gulation of lipid metabolism. Despite the increase in triglyceride
levels, all the treated animals were clinically healthy.
Lopinavir measurement by high-performance liquid chromatography
The drug concentrations in the blood samples were measured by
high-performance liquid chromatography (HPLC) as described previ-
ously (Frappier et al., 1998), withminor modiﬁcations. Brieﬂy, plasma
samples collected from two monkeys were subjected to deproteiniza-
tion by the addition of acetonitrile, and were subsequently loaded
onto a HPLC column. The assay conditions were as follows: column,
ODS column (150 mm in length and 4.6 mm in diameter; Cadenza);mobile phase, gradient prepared from two solutions (solution A,
0.1% triﬂuoroacetic acid [TFA] in water; solution B, 0.1% TFA in aceto-
nitrile). The total ﬂow rate was 0.6 ml/min. For detection of the com-
pound, UV absorbance at a wavelength of 215 nm was employed.
Plasma viral RNA measurement
Viral RNA loads in plasma were measured as described previously
(Miyake et al., 2006). Brieﬂy, total RNA was extracted from plasma sam-
ples with the QIAamp Viral RNA kit (Qiagen, Valencia, CA). The extracted
RNA samples were subjected to RT-PCR to amplify the SIV gag region
using the TaqMan EZ RT-PCR kit (PerkinElmer, Wellesley, MA). The PCR
and detection of products were performed in a Prism 7700 Sequence De-
tector (Applied Biosystems, Foster City, CA). The primer pair employed for
PCR ampliﬁcation was SIV2-696F (5′-GGAAATTACCCAGTACAACAAA-
TAFF-3′) and SIV2-784R (5′-TCTATCAATTTTACCCAggCATTTA-3′). PCR
products were detected with a labeled probe, SIV2-731T (5′-Fam-
TGTCCACCTGCCATTAAGCCCG-Tamra-3′; Perkin Elmer).
Selected plasma samples from monkeys on cART (at 29, 42, and
52 weeks pi, and at euthanasia) were further subjected to quantita-
tive real-time PCR with a lower detection limit, following the method
described by Cline et al., with modiﬁcations (Cline et al., 2005). Brief-
ly, 1.5-ml plasma samples were centrifuged at 20,000×g for 1 h to
sediment virus particles. The pellets were incubated with a mixture
of GuHCl (Sigma-Aldrich) and proteinase K (Invitrogen) for 60 min
at 37 °C and subsequently incubated with a mixture of GuSCN
(Sigma-Aldrich) and glycogen (Roche Applied Science, Indianapolis,
IN) for 5 min at room temperature, followed by precipitation with
isopropanol. The precipitated RNA fractions were resuspended in
water and subjected to RT-PCR, as described above. A standard
curve of the reaction was constructed by plotting threshold cycles of
serially diluted virus stocks containing known amounts of vRNA
extracted in the same manner as the test plasma samples. The detec-
tion limit was deﬁned by the standard curve with a correlation coef-
ﬁcient (>0.96) constructed from a set of serial dilutions with
reproducible ampliﬁcation. The detection limit of the assay was con-
sistently b20 copies/ml.
Mathematical modeling and statistical analysis of decay rate
The decline in SIV239 RNA copies in the plasma during cART was
evaluated using a mathematical model similar to that developed pre-
viously to quantify and analyze the decay of HIV-1 viremia in patients
treated with combination anti-retroviral therapy (Perelson et al.,
1997). Brieﬂy, two distinct cellular compartments are assumed to
contribute to the vRNA. The ﬁrst compartment consists of CD4+ T
cells (i.e., short-lived cells), T, which are infected with a constant, k,
die with a rate constant, δ, and have a burst size of N. The second com-
partment consists of long-lived cells, M, which become infected with
a rate constant, kM, die with a rate, μM, and produce p virions per cell.
Free virus particles are cleared with a constant, c. Assuming that viral
inhibition by cART is 100%, de novo infection is completely blocked in
this mathematical model. Then, using the parameters explained
above, the overall vRNA copies in the plasma can be described by
the following equation:














Here, V0 and T0 are the steady-state level of viral load and CD4+ T
cells count before HAART, respectively. The derivation of Eq. (1) is
explained in detail elsewhere (Perelson and Nelson, 1999). To ﬁt the
plasma viremia data with the two-compartment model, we estimated
the parameters, δ, μM, and a composite parameter, NkT0, employing
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tica ver. 7.0 software). Since virion clearance occurs too rapidly to esti-
mate c from the available data in Rhesus macaques, we ﬁxed c=62.1
(determined previously) (Igarashi et al., 1999), although the change in
c did not signiﬁcantly change in our parameter estimates (data not
shown). To derive the 68% conﬁdence interval for each parameter, we
employed a bootstrap method (Efron, 1979; Efron and Tibshirani,
1986) in which each experiment was simulated 1000 times. Statistical
comparisons for continuously distributed variables between groups
were performedwithWelch's test. Nominal P-values b0.05were consid-
ered statistically signiﬁcant and all tests were two-sided.
Necropsy and tissue collection
All the animals were subjected to perfusion/euthanasia, as de-
scribed previously (Igarashi et al., 2002), with minor modiﬁcations.
Brieﬂy, animals anesthetized with ketamine/xylazine were intrave-
nously administered pentobarbital sodium (50 mg/kg body weight,
Nembutal; Abbott Laboratories) before thoracotomy. The right atrium
was incised and one liter of sterile saline anti-coagulated with hepa-
rin (5 U/ml) was introduced into the left ventricle via a 16G needle at-
tached to infusion tubing. Peripheral blood was collected prior to
perfusion. During the perfusion, tissue collection was conducted. Col-
lected tissues were trimmed and placed into two independent work-
ﬂows: submersion in RNAlater (Qiagen) and stored at −20 °C until
RNA extraction, and ﬁxation in 4% paraformaldehyde in PBS at 4 °C
overnight, followed by embedding in parafﬁn wax for histopathologic
analyses. The list of collected tissues is summarized in Table 5.
Isolation, quantiﬁcation, and statistical analysis of viral RNA from tissues
Tissues submerged in RNAlater and stored at −20 °C were sub-
jected to total RNA extraction using TRIzol reagent (Invitrogen)
according to the manufacturer's recommendations. Brieﬂy,
50–100 mg of each tissue resuspended in 1 ml of TRIzol reagent
were homogenized with Lysing Matrix D (MP Biomedicals, Irvine,
CA) using FastPrep FP120 (MP Biomedicals). Chloroform (0.2 ml)
was added to the homogenate, and the aqueous phase was collected
to a new tube after centrifugation at 12,000×g for 15 min at 4 °C.
The aqueous phase was mixed with 0.5 ml isopropanol, and the su-
pernatant was removed after centrifugation at 12,000×g for 10 min
at 4 °C. Then, 1 ml of 75% ethanol was added to the pellet and, after
centrifugation at 7500×g for 5 min at 4 °C, the supernatant was
cleared. The total RNA sample was resuspended in RNase-free water
and frozen at −80 °C until use. The amount of RNA extracted from
each tissue specimen was measured in a UV spectrophotometer
(UV-1600; Shimadzu, Kyoto, Japan). Aliquots (1 μg) of RNA extracted
from the various tissue samples were subjected to RT-PCR, to amplify
the SIV gag region. The amounts of vRNA detected by PCR in a variety
of tissues from treated animals and untreated controls, as described
below, were compared using a Mann–Whitney test and GraphPad
Prism software (GraphPad, La Jolla, CA).
Immunohistochemistry
Viral-protein-producing cells were visualized with an anti-SIV an-
tibody and anti-CD35 antibody, as described previously (Inaba et al.,
2009), with minor modiﬁcations. Brieﬂy, tissue sections (4-μm thick-
ness) were dewaxed with xylene, rehydrated through an alcohol gra-
dient, submerged in Target Retrieval Solution (DAKO, Glostrup,
Denmark), and processed in an autoclave for 10 min to unmask the
antigens. Subsequently, the tissue sections were washed with Tris-
buffered saline/Tween-20 (TBST), treated with REAL Peroxidase-
Blocking Solution (DAKO) for 5 min, to deactivate endogenous perox-
idase, and washed with TBST. The sections were incubated with an
anti-SIV Nef mouse monoclonal antibody (diluted 1:500, clone 04-001; FIT Biotech, Tampere, Finland) at 4 °C overnight. After washing
with TBST, the sections were incubated at room temperature for
30 min with the Envision+ kit (a horseradish peroxidase-labeled
anti-mouse immunoglobulin polymer; DAKO), washed with TBST, vi-
sualized using diaminobenzidine (DAB) substrate (DAKO) as the
chromogen, and rinsed in distilled water. Subsequently, the sections
were treated at 95 °C for 10 min with Target Retrieval Solution
(DAKO), to deactivate the antibody added upstream in the procedure,
washed with TBST, and incubated with the anti-CD35 mouse mono-
clonal antibody (diluted 1:50, clone Ber-MAC-DRC; DAKO) at 4 °C
overnight. After washing, the slides were incubated with Histoﬁne
Simple Stain AP (an alkaline phosphatase-labeled anti-mouse immu-
noglobulin polymer; Nichirei, Tokyo, Japan) at room temperature for
30 min, and washed with TBST. The speciﬁc antigen-antibody reac-
tion was visualized with Blue Alkaline Phosphatase Substrate Kit III
(Vector Laboratories, Burlingame, CA). The stained sections were ex-
amined under an Axiophot Universal microscope (Carl Zeiss, Oberko-
chen, Germany), and images were captured with the Nikon Digital
Sight DS-Fi1 camera head and Nikon Digital Sight DS-L2 control unit
(Nikon, Tokyo, Japan).
To identity the Nef-producing cells, slides of the tissue were
stained with the anti-SIV antibody and anti-CD3 antibody. Sections
were subjected to dewaxing and unmasking of antigens, as described
above. Subsequently, the sections were incubated with the anti-SIV
Nef mouse monoclonal antibody (diluted 1:500, clone 04-001; FIT
Biotech) at 4 °C overnight. After washing with TBST, the sections
were incubated at room temperature for 30 min with anti-CD3 rabbit
polyclonal antibody (diluted 1:50; DAKO), and washed with TBST.
The sections were treated with Alexa Fluor 488 (diluted 1:200,
ﬂuorochrome-conjugated goat anti-mouse immunoglobulin G; Mo-
lecular Probes, Eugene, OR) and Alexa Fluor 594 (diluted 1:200;
ﬂuorochrome-conjugated goat anti-rabbit immunoglobulin G; Molec-
ular Probes) for 1 h, to visualize the bound anti-SIV Nef antibody and
anti-CD3 antibody, respectively. The stained sections were examined
using a Leica TCS SP2 AOBS confocal microscope (Leica Microsystems,
Exton, PA) and the Leica image software (Leica Microsystems). Sec-
tions prepared from an SIV-infected monkey (MM521) and unin-
fected monkeys were stained in the same manner as those from
cART and post-cART animals, as controls for the staining (Supplemen-
tal Fig. 3).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.11.024.
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